Clinical trials: Metastatic Solid Tumor Cancer
Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
This pilot clinical trial studies how well voxel based diffusion tensor imaging in predicting response in patients with brain metastases undergoing whole-brain radiation therapy or stereotactic radiosurgery.
- Trial name
- NCT02277561
- Testing
- diffusion tensor imaging, whole-brain radiation therapy, stereotactic radiosurgery
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20…
- Trial name
- NCT06616766
- Testing
- YH42946
- Where
- 8 sites in United States, South Korea
- Volunteers
- 201 people
- Sponsor
- Yuhan Corporation
Advanced or Metastatic Solid Tumor Malignancies
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044…
- Trial name
- NCT05023486
- Testing
- NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy
- Where
- 18 sites in United States
- Volunteers
- 121 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT05136196
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 232 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and…
- Trial name
- NCT07534813
- Testing
- GT307 injection
- Where
- China
- Sponsor
- Grit Biotechnology
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 14 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
FAP
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
The aim of this study is to assess the safety of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic Fibroblast Activation Protein (FAP)-positive solid tumors and to establish a…
- Trial name
- TheraTri (NCT06640413)
- Testing
- [177Lu]Lu-OncoFAP-23, L19IL2
- Where
- 4 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Philogen S.p.A.
Colorectal Cancer
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment…
- Trial name
- NCT00721916
- Testing
- SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
- Where
- Japan
- Volunteers
- 107 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Solid Tumor
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.
- Trial name
- PEG (NCT00834704)
- Testing
- PEGPH20
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Solid Tumor, C-Met Mutation-Related Tumors
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple…
- Trial name
- NCT04228406
- Testing
- GST-HG161
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
Solid Tumor
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).
- Trial name
- NCT05217693
- Testing
- BB-1705
- Where
- 7 sites in China
- Volunteers
- 288 people
- Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
Safety and Early Signs of Efficacy of IL12-L19L19.
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune…
- Trial name
- DODEKA (NCT04471987)
- Testing
- IL12-L19L19
- Where
- 11 sites in Germany, Italy and 1 more
- Volunteers
- 80 people
- Sponsor
- Philogen S.p.A.
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
Breast Cancer
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT)…
- Trial name
- NCT05339685
- Testing
- BL-M02D1
- Where
- 10 sites in China
- Volunteers
- 82 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Palliative Radiotherapy, Metastatic Cancer (Different Solid Tumour Types)
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART.
- Trial name
- HART (NCT06778408)
- Testing
- Hybrid Palliative Radiation Therapy
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Vermont Medical Center
Solid Tumor, Adult
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and…
- Trial name
- OASIS (NCT06063317)
- Testing
- CF33-CD19 IT Monotherapy, CF33-CD19 IV Monotherapy, CF33-CD19 IT Combination
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Imugene Limited
Solid Tumor
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent by IV infusion every 3 weeks to patients with…
- Trial name
- NCT05360368
- Testing
- HLX07
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005791
- Testing
- cisplatin, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.